(17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl) hydrogen sulfate → Glycine

HRID 1168121

Reaktionsgleichung

Reaktionsgleichung von HRID 1168121
CC(C1C2(C)CCC3C4(C)CCC(OS(O)(=O)=O)CC4=CCC3C2CC1)=O.[CH3:28][NH:29][C@@H:30]([C:35]([OH:37])=[O:36])[CH2:31][C:32]([OH:34])=[O:33]>>[CH3:28][NH:29][C@@H:30]([C:35]([OH:37])=[O:36])[CH2:31][C:32]([OH:34])=[O:33].[NH2:29][CH2:30][C:35]([OH:37])=[O:36]

Komponenten

4

Edukt 2

HCID 4903(17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl) hydrogen sulfateHCID 22880Nmda

Produkt 2

HCID 750GlycineHCID 22880Nmda

Versuchsvorschrift

FIG. 19 contains two graphs of data indicating pregnenolone sulfate (PS) differentially modulate NR1011/2A and NR1111/2A splice variants at pH 8.5. Data points are averaged normalized peak NMDA-induced current responses obtained from oocytes injected with (A) NR1011/2A or (B) NR1111/2A mRNAs. Concentration-response data for NMDA (circles) and for NMDA+100 μM PS (squares) were obtained in the presence of 10 μM glycine. Fitted parameters are (A) (control ◯, n=11), EC50=94 μM, Emax=1.30, nH=1.62; (+PS, open squares, n=10), EC50=58 μM, Emax=1.62, nH=1.44; (B) (control, closed circles, n=10), EC50=110 μM, Emax=1.35, nH=1.93; (+PS, closed squares, n=23), EC50=94 μM, Emax=1.98, nH=1.82. The data were normalized relative to the current induced by co-application of 200 μM NMDA and 10 μM glycine to the same oocyte. Error bars represent S.E.M.

Aufarbeitung

  1. customobtained from oocytes
  2. concentrationConcentration-response data for NMDA (circles)

Quellen und Nachweise

ORD-Eintrag
ord-5fd51153d72745a58a5f867ed66e51b4
Quelldatensatz
uspto-grants-2003_09
Patentnummer
US06623933B1

Verknüpfte Notizen

Wird geladen…